| Autor: |
David Staskin, Jeffrey Frankel, Susann Varano, Michael Kennelly, Diane K. Newman, Matt T. Rosenberg, Denise D. Shortino, Rachael A. Jankowich, Paul N. Mudd Jr |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
International Journal of Clinical Practice, Vol 2022 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1742-1241 |
| DOI: |
10.1155/2022/6475014 |
| Popis: |
Background. Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a selective β3-adrenergic receptor agonist for the treatment of OAB—significantly improved daily number of urgency episodes and micturitions vs. placebo (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text